China smartphone shipments slumped in June on inventory overhang: Jefferies
SAN DIEGO—Sadie Stern (AS:PBHP), Executive Vice President and Chief HR Officer at Dexcom Inc. (NASDAQ:DXCM), a $34.08 billion medical device company trading near its 52-week high of $128.63, has sold 6,184 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The transaction, executed on May 27, 2025, was carried out under a pre-established 10b5-1 trading plan.
The shares were sold at a weighted average price of $85.1097, with individual trades executed at prices ranging from $84.75 to $85.445. Following the sale, Stern retains ownership of 109,621 shares, including 74,450 unvested restricted stock units. These unvested units are set to vest over the next few years, with specific vesting schedules outlined in the filing. According to InvestingPro data, Dexcom maintains strong financial health with a "GREAT" overall score, despite trading at elevated earnings multiples.
Stern’s transaction exemplifies the use of 10b5-1 plans, which allow company insiders to set up a predetermined schedule for selling stocks to avoid potential accusations of insider trading. InvestingPro analysis reveals Dexcom’s solid fundamentals, with 9.11% revenue growth and positive earnings, though currently trading above its Fair Value. Subscribers can access 12 additional ProTips and comprehensive valuation metrics in the Pro Research Report.
In other recent news, DexCom reported first-quarter revenue of $1.04 billion, surpassing analyst expectations of $1.02 billion, marking a 12% increase year-over-year on a reported basis and 14% on an organic basis. However, the adjusted earnings per share were slightly below expectations at $0.32, missing the $0.33 forecast. DexCom’s U.S. revenue saw a 15% year-over-year increase, while international revenue grew 7% on a reported basis and 12% organically. The company reiterated its full fiscal year 2025 revenue guidance of $4.60 billion and announced a $750 million share repurchase program.
BTIG raised its price target for DexCom to $109 from $107, maintaining a Buy rating, following the company’s strong first-quarter performance. Canaccord Genuity also adjusted its price target to $106 from $103, highlighting DexCom’s robust U.S. sales and potential in the Type 2 non-insulin market. Meanwhile, Bernstein lowered its price target to $88 from $100 but maintained an Outperform rating, citing revised sales estimates and a lower price-to-sales multiple due to potential risks. RBC Capital Markets reiterated an Outperform rating with a $100 target, noting the potential for significant growth driven by expanded U.S. Pharmacy Benefit Manager coverage and increasing profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.